Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/UBE2M_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/UBE2M_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/UBE2M_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/UBE2M_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/UBE2M_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/UBE2M_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:0051402110 | Esophagus | ESCC | neuron apoptotic process | 148/8552 | 246/18723 | 3.08e-06 | 3.47e-05 | 148 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
GO:1901216111 | Esophagus | ESCC | positive regulation of neuron death | 65/8552 | 97/18723 | 1.76e-05 | 1.56e-04 | 65 |
GO:0043525110 | Esophagus | ESCC | positive regulation of neuron apoptotic process | 40/8552 | 58/18723 | 2.83e-04 | 1.71e-03 | 40 |
GO:004352317 | Esophagus | ESCC | regulation of neuron apoptotic process | 122/8552 | 212/18723 | 3.21e-04 | 1.90e-03 | 122 |
GO:004511614 | Esophagus | ESCC | protein neddylation | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
GO:007099712 | Liver | Cirrhotic | neuron death | 141/4634 | 361/18723 | 9.56e-10 | 4.38e-08 | 141 |
GO:19012147 | Liver | Cirrhotic | regulation of neuron death | 122/4634 | 319/18723 | 5.17e-08 | 1.62e-06 | 122 |
GO:00514027 | Liver | Cirrhotic | neuron apoptotic process | 91/4634 | 246/18723 | 1.18e-05 | 1.68e-04 | 91 |
GO:00435236 | Liver | Cirrhotic | regulation of neuron apoptotic process | 77/4634 | 212/18723 | 1.08e-04 | 1.10e-03 | 77 |
GO:19012167 | Liver | Cirrhotic | positive regulation of neuron death | 41/4634 | 97/18723 | 1.13e-04 | 1.14e-03 | 41 |
GO:0045116 | Liver | Cirrhotic | protein neddylation | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:00435257 | Liver | Cirrhotic | positive regulation of neuron apoptotic process | 25/4634 | 58/18723 | 1.66e-03 | 1.07e-02 | 25 |
GO:007099722 | Liver | HCC | neuron death | 202/7958 | 361/18723 | 1.44e-07 | 2.70e-06 | 202 |
GO:190121412 | Liver | HCC | regulation of neuron death | 179/7958 | 319/18723 | 5.65e-07 | 9.01e-06 | 179 |
GO:190121612 | Liver | HCC | positive regulation of neuron death | 62/7958 | 97/18723 | 1.67e-05 | 1.81e-04 | 62 |
GO:005140212 | Liver | HCC | neuron apoptotic process | 135/7958 | 246/18723 | 5.64e-05 | 5.26e-04 | 135 |
GO:004352512 | Liver | HCC | positive regulation of neuron apoptotic process | 39/7958 | 58/18723 | 1.22e-04 | 1.02e-03 | 39 |
GO:004352312 | Liver | HCC | regulation of neuron apoptotic process | 117/7958 | 212/18723 | 1.25e-04 | 1.03e-03 | 117 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa0412025 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
hsa0412035 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0412019 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0412024 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
hsa0412034 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UBE2M | SNV | Missense_Mutation | novel | c.524N>G | p.Ser175Cys | p.S175C | P61081 | protein_coding | deleterious(0.01) | benign(0.116) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
UBE2M | insertion | Nonsense_Mutation | novel | c.450_451insCCAGGCTATTAAAGGGGAATGTTACTGCATG | p.Glu151ProfsTer4 | p.E151Pfs*4 | P61081 | protein_coding | | | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
UBE2M | SNV | Missense_Mutation | novel | c.244N>A | p.Val82Met | p.V82M | P61081 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
UBE2M | SNV | Missense_Mutation | novel | c.486N>C | p.Gln162His | p.Q162H | P61081 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
UBE2M | SNV | Missense_Mutation | novel | c.319N>A | p.Glu107Lys | p.E107K | P61081 | protein_coding | deleterious(0) | benign(0.275) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
UBE2M | SNV | Missense_Mutation | novel | c.521G>A | p.Gly174Asp | p.G174D | P61081 | protein_coding | tolerated(0.3) | benign(0.031) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
UBE2M | SNV | Missense_Mutation | novel | c.481N>C | p.Glu161Gln | p.E161Q | P61081 | protein_coding | tolerated(0.21) | benign(0.207) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
UBE2M | SNV | Missense_Mutation | rs747189992 | c.50N>T | p.Ala17Val | p.A17V | P61081 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UBE2M | SNV | Missense_Mutation | | c.235N>G | p.Ser79Gly | p.S79G | P61081 | protein_coding | deleterious(0.01) | benign(0.397) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UBE2M | SNV | Missense_Mutation | novel | c.506G>A | p.Arg169Gln | p.R169Q | P61081 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |